Every cell type we create can give rise to multiple next generation therapies

Every cell, every patient

The revolutionary impact of cell therapies has already become apparent: engineered CAR-T cells are able to cure blood cancers that used to be untreatable. The application of one single cell type sparked the first wave of cell therapy companies. 

bit.bio is working to generalise this approach across the whole spectrum of human cell types, and to make it accessible.

We are building a therapeutic pipeline across three key focus areas: liver, immunology and metabolic. And we are working with partners to leverage our platform to discover and develop new cell types for therapies. We believe the possibilities for novel cures are endless. 

Solving the ‘cell’ problem in cell therapy

The biggest hurdle in cell therapy today is access to consistent batches of human cell types at scale. 

Therapeutic development needs trillions of cells at an affordable cost in order to generate medicines that are accessible to millions of patients.

bit.bio’s cell identity coding platform is able to create new defined human cell types that are inherently consistent and scalable. Our approach has the potential to reduce the cost of cell therapies by up to two orders of magnitude.